RASAL1 and cancer: Comprehensive analyses of TCGA revealed common coexisting RASAL1 and PTEN alterations and their association with over‐activation of the PI3K–AKT pathway and poor clinical outcomes of cancer, which was recapitulated in mice with double Rasal1–Pten knockout and worsened by coexisting TP53 alterations.